NEET PG Medical – 2020 – Question – 70
Which of the following anticancer drugs are competitive inhibitors of tyrosine kinase –
a) Imatinib and sunitinib
b) Letrozole
c) Bicalutamide
d) Fulvestrant
Correct Answer – A
Ans. is ‘A’ i.e., Imatinib and sunitinib
Molecular targeted agents
Tyrosine kinase inhibitors
Competitive inhibitors → Imatinib, Nilotinib, Sunitinib, Dasatinib, Erlotinib, Gefitinib, Lapatinib, Sorafenib (Remember all end with ‘ nib’).
Monoclonal antibodies → Cetuximab, panitumumab.
HER2/neu (ERB B2) inhibitors Monoclonal antibody – Trastuzumab.
Targeted antibody → Gemtuzumab (anti CD-33), Rituximab (anti – CD20), Alemtuzumab (anti CD-52).
Vascular endothelial growth factor (VEGF) inhibitor → Monoclonal antibody – Bevacizumab.
Proteosome inhibitors → Bortezomib.
Histone deacetylase inhibitor → Vorinostat DNA – methyltransferase inhibitor → 5-azacytidine, 2-deoxy-5
azacytidine All – trans-retinoic acid.
Biological response modifier – Recombinant IL-2 (aldesleukin, denileukin)
